Table 2

Mechanistic differences between GLP-1 agonist exenatide and DPP-4 inhibitor sitagliptin [31].

Sitagliptin

Exenatide

Significance


Change in FPG (mmol/l)

1.04+/- 0.2

0.83+/-0.2

P = 0.3234

Change in PPG (mmol/l)

2.0 +/-0.3

6.26+/-0.3

P <0.0001*

Insulinogenic index

Yes

Yes- significantly more than sitagliptin

P = 0.0239*

Acute Insulin secretion

Yes

Yes- significantly more than sitagliptin

P = 0.0017*

Reduction in post -prandial glucagon

Yes

Yes- significantly more than sitagliptin

P = 0.0011*

Reduction in gastric emptying

none

Yes- significantly more than sitagliptin

P <0.0001*

Six point SMBG excursions

Post breakfast

Yes- significantly less than sitagliptin

P = 0.0016*

Post lunch

Similar to Sitagliptin

P = 0.07849

Post dinner

Yes- significantly less than sitagliptin

P = 0.038*

Reduction in body weight (kg)

0.3+/-0.2

0.8+/-0.2

P = 0.0056*

Decrement in calorie intake

none

Yes- significantly more than sitagliptin

P = 0.0227*

Reduction in post-prandial triglyceride levels

yes

Yes- significantly more than sitagliptin

P = 0.018*

Nausea

12%

34%

Vomiting

3%

24%


*Statistically significant. DDP-4, dipeptidyl peptidase 4; FPG, fasting plasma glucose; GLP-1, glucagon-like peptide 1; PPG, postprandial glucose; SMBG, self-monitoring blood glucose

Nisal et al. BMC Medicine 2012 10:152   doi:10.1186/1741-7015-10-152

Open Data